Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.
Brunzell
John D
JD
Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, Northwest Lipid Laboratory, University of Washington, Seattle, Washington, USA.
Davidson
Michael
M
Furberg
Curt D
CD
Goldberg
Ronald B
RB
Howard
Barbara V
BV
Stein
James H
JH
Witztum
Joseph L
JL
D053299:Apolipoprotein B-100 / Q000097:blood; D001161:Arteriosclerosis / Q000097:blood / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000097:blood / Q000503:physiopathology* / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008074:Lipoproteins / Q000097:blood*; D018570:Risk Assessment; D012307:Risk Factors; D012955:Societies, Medical; D014280:Triglycerides / Q000097:blood; D014481:United States
D053299:Apolipoprotein B-100; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins; D014280:Triglycerides